Pregnancy Malaria Vaccine development

$244,870ZIAFY2016AINIH

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications, trials & patents

Paper 38437239 Paper 37228009 Paper 35290467 Paper 35103596 Paper 34718641 Paper 33846719 Paper 33452495 Paper 32566259 Paper 30988054 Paper 30621913 Paper 29523137 Paper 29432484 Paper 28984865 Paper 28213434 Paper 27190180 Paper 26469717 Paper 23345587 Paper 23319559

Abstract

Pregnancy malaria (PM) is a major public health problem associated with severe maternal anemia, preeclampsia, pregnancy loss, low birthweight delivery and infant mortality. PM is caused by the sequestration in the placenta of parasites that bind the receptor chondroitin sulfate A (CSA). Previous ex vivo experiments have shown that parasite binding to CSA can be inhibited by antibodies from multigravida women who acquired specific immunity to CSA-binding parasites or by antibodies from animals immunized with antigens that mediate parasite binding to CSA

View original record on NIH RePORTER →